 SAN DIEGO, Sept. 28, 2021 PRNewswire -- Kintara Therapeutics, Inc. Nasdaq: KTRA Kintara or the Company, a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with several healthcare-focused institutional investors of 12,000,000 shares of its common stock or common stock equivalents and warrants to purchase up to an aggregate of 12,000,000 shares of common stock, at a combined offering price of 1.25 per share and associated warrant. 